Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 277 across all filing types
Latest filing 2024-04-05 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
Block Listing Return
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled 'BLOCK LISTING RETURN' and contains an RNS Number (5465J) from the London Stock Exchange. It details the activity of employee share incentive plans (SIP and ESOP) over a specific period (Oct 6, 2023, to Apr 6, 2024), reporting the number of shares issued and the resulting total shares in issue. This type of filing, which reports on the issuance of shares under employee schemes to maintain compliance with listing rules (specifically mentioning Schedule 6 of the AIM Rules for Companies), is a specific regulatory disclosure. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS), but rather a compliance return related to employee plans. Since there is no specific code for a 'Block Listing Return', and it is a mandatory regulatory disclosure distributed via RNS, the most appropriate classification is the general regulatory filing fallback, RNS, as it is a standard compliance document distributed through that service.
2024-04-05 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number' and the closing statement referencing RNS and the London Stock Exchange). The content explicitly details share transactions by Persons Discharging Managerial Responsibilities (PDMRs) under share incentive plans, referencing 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014'. This type of insider transaction disclosure is specifically covered by the 'Director's Dealing' category (DIRS). Although it is an RNS filing, the specific content points directly to DIRS, which takes precedence over the general RNS fallback.
2024-04-03 English
Director/PDMR/PCA Shareholding & TR1
Director's Dealing Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number : 8170I' and the closing boilerplate referencing RNS and the FCA). The content explicitly details the 'Sale' of shares by an 'Executive Director' and a 'PCA' (Person Closely Associated), which falls under insider trading or director's dealing regulations (MAR Article 19). The document includes structured tables for 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014' and a 'TR-1: Standard form for notification of major holdings'. This content directly matches the definition of Director's Dealing (DIRS).
2024-04-02 English
Significant upgrade to Diaceutics' DXRX platform
Regulatory Filings Classification · 98% confidence The document starts with 'RNS Number : 6750H' and is dated March 21, 2024. It announces a product launch ('Diaceutics launches significant upgrade to its DXRX platform') and includes contact information for investor relations and brokers, concluding with a disclaimer stating, 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This structure is characteristic of a general regulatory announcement distributed via the RNS system, but it is not a specific financial report (like 10-K or IR) or a specific corporate action (like DIV or DIRS). Since it is a general announcement distributed via RNS and does not fit neatly into the other specific categories, the most appropriate classification is the general Regulatory Filings fallback code.
2024-03-21 English
Diaceutics forms landmark industry Forum
Regulatory Filings Classification · 100% confidence The document begins with 'National Storage Mechanism' and 'RNS Number : 3232H', indicating it is a regulatory announcement distributed via the RNS system. The content announces the establishment of an industry forum by Diaceutics PLC to address economic barriers in precision medicine, including details about co-chairs, members, and an upcoming virtual summit. This is a general corporate announcement regarding an initiative, not a specific financial report (like 10-K, IR, ER) or a formal shareholder vote result (DVA). Since it is a general regulatory announcement distributed via RNS that doesn't fit into the more specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS.
2024-03-19 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official announcement filed via RNS (RNS Number: 9056F) dated March 7, 2024. The title explicitly states 'Director / PDMR Shareholding - NED Purchase of Shares'. It details a transaction where a Non-Executive Director (Graham Patterson) purchased ordinary shares. This directly corresponds to the definition of Director's Dealing (insider trades by directors/executives). The specific regulatory context mentioned (Article 19(1) of Regulation (EU) No. 596/2014) confirms this is a mandatory disclosure of insider transactions. Therefore, the correct classification is DIRS.
2024-03-07 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.